FDA seeks active system for monitoring adverse events

被引：0
|
作者：
Wechsler, Jill
机构：
来源：
BIOPHARM INTERNATIONAL | 2008年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：14 / +
页数：2
相关论文
共 50 条
  • [31] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [32] PAIN AND ARTHRALGIA ADVERSE EVENTS ASSOCIATED WITH CRIZANLIZUMAB AND VOXELOTOR: DISPROPORTIONALITY ANALYSIS OF US FDA ADVERSE EVENTS REPORTING SYSTEM (FAERS)
    Ologunowa, A.
    Caffrey, A. R.
    VALUE IN HEALTH, 2023, 26 (06) : S208 - S208
  • [33] Safety profile of carbapenems: Data mining of the FDA adverse events reporting system
    Ge, Wei
    Hu, Haixia
    Li, Chen
    Wang, Ling
    Xia, Jielai
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (09) : 594 - 602
  • [34] Loperamide adverse events reported to the FDA Medwatch system from 2008 to 2017
    Eggleston, William
    Marrafa, Jeanna
    Nguyen, Mitchell
    Yang, Angela
    Soliman, Sarah
    Hodgman, Michael
    CLINICAL TOXICOLOGY, 2018, 56 (10) : 976 - 977
  • [35] A pharmacovigilance study of FDA adverse events for sugammadex
    Mao, Xiaoyan
    Zhang, Rong
    Liang, Xia
    Liu, Fan
    Dai, Yuan
    Wang, Meng
    Huang, Haoquan
    Fu, Ganglan
    JOURNAL OF CLINICAL ANESTHESIA, 2024, 97
  • [36] FDA Summary of Adverse Events on Electronic Cigarettes
    Chen, Ii-Lun
    NICOTINE & TOBACCO RESEARCH, 2013, 15 (02) : 615 - 616
  • [37] Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
    Roberto, Giuseppe
    Piccinni, Carlo
    D'Alessandro, Roberto
    Poluzzi, Elisabetta
    CEPHALALGIA, 2014, 34 (01) : 5 - 13
  • [38] Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
    Wu, Fan
    Zhu, He
    Zhang, Yue
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [39] Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
    Shu, Yamin
    Chen, Jing
    Ding, Yiling
    Zhang, Qilin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [40] Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kheterpal, Aarushi
    Dhas, Ashwin
    Zeba, Zeba
    Shettigar, Amrutha
    Lukose, Lipin
    Kaur, Gursimran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 452 - 452
12345